bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract IA03: Head and Neck Cancer Takes a Nerve, Cancer neuroscience: emerging hallmark of cancer
Authors: Amit Moran 
Published: September 2023

Abstract
Over the past decade, emerging technologies have enabled investigators to begin to bridge the gap between cancer and neuroscience research to unveil the interactive roles of nerves in cancer. We are now beginning to define how the nervous system contributes to cancer initiation, growth, spread, recurrence, and even resistance to oncologic therapeutic strategies. Indeed, neuromodulation with both genetic and pharmacological approaches has been shown to affect not only tumor growth but also antitumor immune response. Collectively, studies have demonstrated a significant and pressing need to recognize cancer neuroscience interplay as a hallmark of cancer to 1) establish the neoneurogenic process as a highly relevant therapeutic target for both the prevention and treatment of cancer, 2) foster interdisciplinary cross-talk among experts in cancer biology and neuroscience, which have traditionally progressed along parallel paths, and 3) integrate human variables such as biological sex, age, race, and gender as underlying factors that can impact cancer neuroscience.
Citation Format: Moran Amit. Head and Neck Cancer Takes a Nerve, Cancer neuroscience: emerging hallmark of cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr IA03.
Abstract PO-023: The AP-1 transcription factor component, JunB, regulates the expression of HPV genes in head and neck cancer
Authors: Rehmani Hina , Isaeva Natalia , Schrank Travis P. , Yarbrough Wendell G. 
Published: September 2023

Abstract
Within head and neck squamous cell carcinoma (HNSCC), those induced by the human papillomavirus (HPV+) have a more hypermethylated genome compared to those that are negative (HPV-). Therefore, our lab explored the usage of the demethylating agent 5-azacytidine (5-aza), an FDA-approved drug for the treatment of myelodysplasia and acute myeloid leukemia. Repurposing FDA-approved drugs is a strategic way to quickly provide patients with secondary therapeutic options, especially since the incidence of HPV+ HNSCC is now considered an epidemic in the US and Western Europe. Additionally, initial therapy for patients is aggressive leading to adverse, lifelong side effects. Despite having a higher cure rate than HPV-HNSCC, the recurrence rate is still approximately 30% for HPV+ HNSCC. Our lab has found that HPV+ HNSCC cells are more sensitive than HPV- cells to 5-aza as low doses of 5-aza delayed HPV+ xenograft tumor growth and 5-aza-treated HPV+ tumor samples from patients treated in a window trial had increased cell death. Despite demethylation inducing an active, open chromatin conformation, we also observed a marked downregulation of HPV genes expression after 5-aza. Decreased HPV E6 expression, followed by reactivation of tumor suppressor p53, induced p53-dependent apoptosis in HPV+ HNSCC. This decreased expression of HPV genes is an essential component of 5-aza-associated toxicity toward HPV+ HNSCC. Our lab has recently explored the molecular mechanisms of 5-aza on HPV+ HNSCC. We found that 5-aza transcriptionally downregulated the expression of HPV genes, including oncogenes E6 and E7. Microarray studies show marked downregulation of the proto-oncogene JunB, a component of the transcription factor AP-1 (Activator Protein 1) after 5-aza treatment. Experimental deletion of JunB inhibited oncogenes E6 and E7 and restored p53 but also indicated that untreated HPV+ HNSCCs depend on JunB for clonogenic growth. Through this study, we have identified a novel dependency on JunB in HPV+ HNSCC and revealed a new rational target that is desperately needed to treat recurrent/metastatic patients and decrease the toxicity associated with current treatment.
Citation Format: Hina Rehmani, Natalia Isaeva, Travis P. Schrank, Wendell G. Yarbrough. The AP-1 transcription factor component, JunB, regulates the expression of HPV genes in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-023.
Abstract PO-080: Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
Authors: Kwon Minsu , Lee Yoon Se , Jung Hanul , Kim Min Ji , Kang So Hee , Seo Ji-Hyun , Park Jung Je 
Published: September 2023

Abstract
The purpose of this study was to determine whether statins can enhance anticancer effects in head and neck squamous cell carcinoma (HNSCC) when used with cisplatin and act as immunogenic cell death (ICD) inducers that can be used in cancer immunotherapy. Statins alone showed both in vitro and in vivo inhibitory effects against HNSCC, and synergistic antitumor effects were observed when combined with cisplatin in a syngeneic murine HNSCC model. Statins increased calreticulin exposure and endoplasmic reticulum stress-related signals in HNSCC cells. In addition, it was confirmed that statins could activate antigen-presenting cells and tumor-specific CD8+ T cells with an increase in their numbers in the tumor tissues and draining lymph nodes, with this effect showing significant improvement following the combination therapy with cisplatin. Moreover, in triple combination with both cisplatin and anti-programmed cell death 1 receptor (anti-PD-1) antibody, statins dramatically induced further tumor eradication and improved the survival of tumor-bearing mice. Taken together, these results demonstrate that statins, administered in combination with anti-PD-1 antibody, could enhance the anticancer effect of cisplatin and potentiate the efficacy of immunotherapy for HNSCC and present a rationale for repurposing statins as an adjuvant immunotherapeutic option for HNSCC.
Citation Format: Minsu Kwon, Yoon Se Lee, Hanul Jung, Min Ji Kim, So Hee Kang, Ji-Hyun Seo, Jung Je Park. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-080.
Abstract PO-091: Leveraging tissue-resident CD103+ NK cells for adoptive cell therapy in head and neck cancer
Authors: Horowitz Nina B. , Shin June Ho , Maddineni Sainiteesh , Mohammad Imran A. , Liu Alice Xinyuan , Sunwoo John B. 
Published: September 2023

Abstract
A major obstacle for all cell therapy of solid tumors has been the ability of adoptively transferred cells to infiltrate into immunosuppressive solid tumor microenvironments. In this study, we developed a method of differentiating and expanding a novel subset of tissue-resident natural killer (NK) cells and assessed their capacity to infiltrate head and neck squamous cell carcinoma (HNSCC) and control tumor growth in vivo. In previous work, single-cell RNA sequencing was performed to profile the entire innate lymphoid cell (ILC) family of lymphocytes (including NK cells) isolated from primary human head and neck squamous cell carcinoma (HNSCC). This revealed multiple subsets of NK cell and ILC states within the tumors. A particular NK cell state, resembling intraepithelial ILC1s (ieILC1), expressed integrins characteristic of tissue residency (such as CD103) and expressed the highest levels of granzyme A, granzyme B, and perforin, suggesting potent cytolytic activity. In the current study, we investigated the potential of these cells for adoptive cell immunotherapy against solid tumors, such as HNSCC and melanoma. Using a co-culture system, we developed a method to differentiate and expand a highly purified population of human CD103+ ieILC1-like NK cells ex vivo to clinically relevant numbers. In vitro impedance-based killing assays were used to assess and demonstrate that these cells have superior cytolytic activity against a variety of epithelial target cells, compared to conventional NK cells. In vivo mouse models using xenografts of HNSCC and melanoma in NSG mice were used to assess and demonstrate superior capacity of ieILC1-like NK cells to control tumor growth compared to conventional NK cells from the same donor. Importantly, the CD103+ ieILC1-like NK cells were able to infiltrate the tumor microenvironment significantly better than conventional NK cells, which likely contributed to their potent control of tumors in vivo. Thus, these findings introduce a novel subset of immune cells that have efficient tumor-infiltrating capacity and potent cytolytic activity for adoptive cell therapy of solid tumors. Because conventional NK cells have already demonstrated clinical activity, these preclinical data indicate that CD103+ ieILC1-like NK cells warrant investigation in the clinic.
Citation Format: Nina B. Horowitz, June Ho Shin, Sainiteesh Maddineni, Imran A. Mohammad, Alice Xinyuan Liu, John B. Sunwoo. Leveraging tissue-resident CD103+ NK cells for adoptive cell therapy in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-091.
Abstract PR07: Oncogene addition to MYB-NFIB in adenoid cystic carcinomas induced in transgenic mice
Authors: Escamilla-Rivera Vicente , Hu Yuan , Cho Sungman , El-Naggar Adel , Luo Han , Caulin Carlos 
Published: September 2023

Abstract
Adenoid cystic carcinoma (ACC) is a slow-growing salivary gland malignancy. The frequent occurrence of chromosome t(6;9) translocations, resulting in MYB-NFIB fusions, is a hallmark of ACC. Approximately, 50% of all ACCs studied to date have been shown to express MYB-NFIB chimeric transcripts, suggesting a prominent role in ACC tumorigenicity. However, the potential relevance of chimeric MYB-NFIB proteins in the development and progression of ACC remains poorly understood. To assess the role of MYB-NFIB in ACC development, we generated transgenic mice in which MYB-NFIB is overexpressed in salivary and mammary glands, using a doxycycline-inducible system. Importantly, a subset of these mice developed ACCs, suggesting that MYB-NFIB is an oncogenic driver of ACC. Using this reversible inducible model, we investigated whether MYB-NFIB was required to maintain established tumors. We found that suppression of the MYB-NFIB transgene upon exposure to doxycycline (Dox) promoted a rapid tumor regression. Tumoral volumes decreased by more than 50 % after only 10 days of starting Dox. This reduction in volume was accompanied by a transition towards a more organized cellular structure and a reduction in the number of cells positive for Ki-67 and MYB-NFIB. To identify mechanisms involved in tumor regression, we compared the transcriptomes from biopsies collected from salivary tumors prior to MYB-NFIB suppression with those from the same tumors after Dox-induced regression. We found that tumor regression upregulated immune-related pathways and promoted T cell infiltration. Additionally, several pathways were downregulated by MYB-NFIB suppression; particularly NOTCH signaling, Cyclin D1-CDK4/6, and Wnt/beta-catenin signaling. We then confirmed, by immunohistochemistry, that tumor biopsies taken before Dox had a higher number of cells positive for Cdk6, CyclinD1, and nuclear beta-catenin. Our results suggest that proteins in these pathways could be used as potential therapeutic targets in MYB-NFIB-driven ACCs.
Citation Format: Vicente Escamilla-Rivera, Yuan Hu, Sungman Cho, Adel El-Naggar, Han Luo, Carlos Caulin. Oncogene addition to MYB-NFIB in adenoid cystic carcinomas induced in transgenic mice [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PR07.
Atoms for Peace in the 1950s: Lessons from the Spread of Nuclear Technology in the Early Cold War
Authors: Josephson Paul R. 
Published: September 2023

Abstract
The articles in this special issue shed light on the influence of the Eisenhower administration's “Atoms for Peace” proposal on the civilian nuclear programs of five European countries, including Italy and France, which were member-states of the North Atlantic Treaty Organization (NATO); Hungary and Czechoslovakia, which were part of the USSR's Communist bloc; and Spain, which did not become a member of NATO until nearly three decades later. Based on detailed archival research, the articles analyze the commercial, scientific, practical, and cultural aspects of nascent nuclear research programs in these five countries. The authors demonstrate that all five acted early on to pursue peaceful nuclear activities for their own economic benefit.
Constructing Nuclear Culture under Soviet-Style Communism: The Hungarian Experience
Authors: Palló Gábor , Adamson Matthew 
Published: September 2023

Abstract
In the mid-1950s, Atoms for Peace provided a crucial boost for the study of nuclear physics in Hungary, a country that fell under Communist rule and Soviet domination after World War II. Several small, insulated centers of nuclear research already existed, but after President Dwight Eisenhower's speech to the United Nations General Assembly on 3 December 1953, calling for the development of Atoms for Peace programs, Hungary's efforts began to grow quickly. In the glow of the moment, with significant support from the government and the ruling Communist party, Hungarian physicists established new research centers, bought and constructed instruments, published specialized books and journals, held conferences, and organized university courses and programs to train experts both at home and in the USSR. These activities constituted a new, vibrant nuclear culture encompassing diverse areas of life (agriculture, medicine, and some parts of industry) and eventually some cooperative links with Western and Soviet-bloc scientific communities.
Evidence of Impaired Remote Experience-near Semantic Memory in Medial Temporal Lobe Amnesia
Authors: Grilli Matthew D. , Sabharwal-Siddiqi Sameer , Thayer Sean C. , Rapcsak Steven Z. , Ekstrom Arne D. 
Published: September 2023

Abstract
Neuropsychological research suggests that “experience-near” semantic memory, meaning knowledge attached to a spatiotemporal or event context, is commonly impaired in individuals who have medial temporal lobe amnesia. It is not known if this impairment extends to remotely acquired experience-near knowledge, which is a question relevant to understanding hippocampal/medial temporal lobe functioning. In the present study, we administered a novel semantic memory task designed to target knowledge associated with remote, “dormant” concepts, in addition to knowledge associated with active concepts, to four individuals with medial temporal lobe amnesia and eight matched controls. We found that the individuals with medial temporal lobe amnesia generated significantly fewer experience-near semantic memories for both remote concepts and active concepts. In comparison, the generation of abstract or “experience-far” knowledge was largely spared in the individuals with medial temporal lobe amnesia, regardless of whether the targets for retrieval were remote or active concepts. We interpret these findings as evidence that the medial temporal lobes may have a sustained role in the retrieval of semantic memories associated with spatiotemporal and event contexts, which are cognitive features often ascribed to episodic memory. These results align with recent theoretical models proposing that the hippocampus/medial temporal lobes support cognitive processes that are involved in, but not exclusive to, episodic memory.
IKS and Gendered Ecologies
Authors: Human Christina , Cawood Stephanie , van As Liesl L. 
Published: September 2023

Abstract
Two geological fault lines mark the southernmost tip of the Great East African Rift Valley. An ancient tectonic uplift, or superswell, caused rifting down the spine of the African continent, which created the Okavango Delta, an endorheic (enclosed) wetland in Botswana. The huge and biodiverse waterbody is an anomaly, as it is surrounded by the otherwise arid Kalahari Desert. Part of this delta is known as the Panhandle. Despite evidence of the Anthropocene, the area teems with massive concentrations of wildlife. It is also home to a diverse post/colonial concentration of human inhabitants, some Indigenous. Each segment of this population has a unique relationship with the environment, informed by Indigenous knowledge systems (IKS), geopolitical hierarchies and the misogynistic politics of the post/colonial nation-state in which hegemonic patriarchies produce gendered ecologies. Through a breaking rank methodology, this paper explores the gendered ecologies and IKS of the post/colonial Panhandle community.
Evidence-based interventions for reducing sickle cell disease-associated morbidity and mortality in sub-Saharan Africa: A scoping review
Authors: Arji Emmanuel Emenike , Eze Ujunwa Justina , Ezenwaka Gloria Oluchukwu , Kennedy Neil 
Published: September 2023

Objective: Sickle cell disease is a lifelong illness affecting millions of people globally, but predominantly burdensome in sub-Saharan Africa, where most affected children do not live to adulthood, despite available evidence-based interventions that reduce the disease burden in high-income countries. Method: We reviewed studies evaluating evidence-based interventions that decrease sickle cell disease-related morbidity and mortality among children living in sub-Saharan Africa. We used the Joanna Briggs scoping review methodological framework and grouped identified evidence-based interventions into preventative pharmacotherapeutic agents, newborn screening and comprehensive healthcare, disease-modifying agents, nutritional supplementation, systemic treatment, supportive agents and patient/carer/population education. Results: We included 36 studies: 18 randomized controlled trials, 11 observational studies, 5 before-and-after studies and 2 economic evaluation studies, with most of the studies performed in West African countries. Included studies suggest evidence-based interventions effectively to reduce the common morbidities associated with sickle cell disease such as stroke, vaso-occlusive crisis, acute chest syndrome, severe anaemia and malaria infection. Evidence-based interventions also improve survival among study participants. Specifically, our review shows hydroxyurea increases haemoglobin and foetal haemoglobin levels, a finding with practical implications given the challenges with blood transfusion in this setting. The feasibility of implementing individual interventions is hampered by challenges such as affordability, accessibility and the availability of financial and human resources. Conclusion: Our review suggests that regular use of low-dose hydroxyurea therapy, sulphadoxine–pyrimethamine chemoprophylaxis, L-arginine and Omega-3 fatty acid supplementation and establishment of specialist stand-alone sickle cell clinics could reduce the sickle cell disease-associated morbidity and mortality in sub-Saharan Africa countries.
Reliability and validity of the Amharic version of immune thrombocytopenia life quality index tool for assessment of the health-related quality of life in Ethiopian patients of immune thrombocytopenia: Cross-sectional study
Authors: Beyene Dessale Abate , Sisay Eskinder Ayalew , Fentie Atalay Mulu , Gebremedhin Amha 
Published: September 2023

Background: Platelet count and bleeding risk are frequently used in clinical assessments of the severity of immune thrombocytopenia. On the other hand, immune thrombocytopenia also influences patients’ health-related quality of life. The immune thrombocytopenia life quality index is a new tool for evaluating health-related quality of life in immune thrombocytopenia patients. Objective: To assess the psychometric properties of the Amharic version of the immune thrombocytopenia life quality index tool for immune thrombocytopenia patients in Ethiopia. Methods: The facility-based cross-sectional study was carried out from 15 September to 30 October 2022. The school of pharmacy institutional ethics review board provided ethical clearance and approval of the study protocol (approval number: ERB/SOP/487/14/2022). Both written informed consent and family or legal guardian consent were obtained for participants aged 14–18 years and informed consent for participants aged >18 years. The tool was forward-backward translated before being pretested on five immune thrombocytopenia patients. Descriptive statistics were used to report sociodemographic and clinical data. The psychometric properties of the immune thrombocytopenia life quality index in Amharic were evaluated for acceptability, reliability, and construct validity. Results: This study included 100 participants, at the age of diagnosis of immune thrombocytopenia, the median with inter-quartile range of platelet count (×109/L) was 15.00 (18.00). The majority of study participants (79, 79%) received prednisolone alone as first-line therapy. The tool psychometric test was reliable; the correlation coefficient between items ranged from 0.147 to 0.956, and the overall Cronbach’s alpha coefficient was 0.956. Furthermore, the tool was construct-valid, with factor analysis between components revealing that Item-1 had an eigenvalue greater than one and explained 72.532% of the total variance among all 10 immune thrombocytopenia life quality index domains. The immune thrombocytopenia life quality index total (alternative score) had a strong ( r = 0.9) correlation with Item-8 and a moderate ( r = 0.317) correlation with Item-5. Conclusion: The Amharic version of the immune thrombocytopenia life quality index tool is a valid and reliable tool that can be used to assess the health-related quality of life of immune thrombocytopenia patients in Ethiopia.